How can including them change our understanding of AI?
Join us for a fascinating interview with Art Ramon, an OmniFuturist and surrealist artist who bridges traditional oil painting with cutting-edge AI art techn…
A new kind of memristor mimics how the brain learns by combining analog and digital behavior, offering a promising solution to the problem of AI “catastrophic forgetting.”
Unlike traditional deep neural networks that erase past knowledge when learning something new, this innovative component may retain previous learning, just like our own brains.
Understanding “Catastrophic Forgetting” in AI.
Jaeb Center for Health Research conducted a randomized controlled trial evaluating the impact of automated insulin delivery (AID) in adults with insulin-treated type 2 diabetes. AID significantly lowered glycated hemoglobin (HbA1c) levels and improved glucose control compared to standard insulin therapy with continuous glucose monitoring (CGM).
AID therapy resulted in a mean HbA1c reduction of 0.9 percentage points over 13 weeks, while the control group experienced a 0.3 percentage point reduction.
Automated insulin delivery systems have demonstrated benefits for patients with type 1 diabetes, yet their efficacy and safety for individuals with type 2 diabetes remain less established. Prior studies have either lacked randomized controlled designs or involved limited sample sizes, creating a gap in clinical understanding.
Scientists have developed shape-shifting nanorobots that can flow like liquid and solidify like steel, paving the way for breakthroughs in medicine, engineering, and robotics. These nanobots, inspired by gallium-based materials, respond to magnetic fields, allowing them to navigate through tight spaces, repair electronics, and even perform medical procedures. While still in the early stages, this futuristic technology could lead to self-healing materials, autonomous repairs, and shape-adaptive robotics, bringing us closer to a world of smart, responsive materials.
A little over a year ago, Joseph Coates was told there was only one thing left to decide. Did he want to die at home, or in the hospital?
Coates, then 37 and living in Renton, Wash., was barely conscious. For months, he had been battling a rare blood disorder called POEMS syndrome, which had left him with numb hands and feet, an enlarged heart and failing kidneys. Every few days, doctors needed to drain liters of fluid from his abdomen. He became too sick to receive a stem cell transplant — one of the only treatments that could have put him into remission.
“I gave up,” he said. “I just thought the end was inevitable.”
But Coates’s girlfriend, Tara Theobald, wasn’t ready to quit. So she sent an email begging for help to a doctor in Philadelphia named David Fajgenbaum, whom the couple met a year earlier at a rare disease summit.
Scientists are using machine learning to find new treatments among thousands of old medicines.